TXG is trading at $37.96 (+2.19%), continuing a strong multi-session recovery fueled by recent positive developments: * The company announced the acquisition of Proteintech Genomics to expand proteomics capabilities. * 10x Genomics entered a multi-year research collaboration with Cleveland Clinic for bladder cancer biomarker discovery. * Canaccord reiterated a 'Buy' rating for TXG, maintaining a price target of $32.00. * The stock also reached a new 52-week high of $37.58 today.